For the quarter ending 2025-09-30, VYGR has $288,311K in assets. $68,486K in debts. $45,125K in cash and cash equivalents.
| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 45,125 | 43,940 | ||
| Marketable securities | 163,805 | 171,653 | ||
| Accounts receivable | 3,186 | 1,674 | ||
| Related party collaboration receivable (see note 8) | 851 | 851 | ||
| Prepaid expenses and other current assets | 6,618 | 9,771 | ||
| Total current assets | 219,585 | 227,889 | ||
| Property and equipment, net | 13,291 | 13,919 | ||
| Restricted cash | 5,614 | 2,874 | ||
| Marketable securities | 20,081 | 46,446 | ||
| Operating lease, right-of-use assets | 29,740 | 30,973 | ||
| Total assets | 288,311 | 322,101 | ||
| Accounts payable | 2,116 | 1,804 | ||
| Accrued expenses | 14,953 | 12,025 | ||
| Operating lease liabilities | 7,848 | 7,637 | ||
| Deferred revenue (see note 8) | 10,578 | 20,517 | ||
| Total current liabilities | 35,495 | 41,983 | ||
| Operating lease liabilities, net of current portion | 30,520 | 32,567 | ||
| Deferred revenue, net of current portion | 1,471 | 2,607 | ||
| Other non-current liabilities | 1,000 | 1,000 | ||
| Total liabilities | 68,486 | 78,157 | ||
| Common stock, 0.001 par value 120,000,000 shares authorized at september 30, 2025 and december 31, 2024 55,482,262 and 54,731,316 shares issued and outstanding at september 30, 2025 and december 31, 2024, respectively | 56 | 56 | ||
| Additional paid-in capital | 638,241 | 634,696 | ||
| Accumulated other comprehensive income (loss) | 7 | -221 | ||
| Accumulated deficit | -418,479 | -390,587 | ||
| Total stockholders' equity | 219,825 | 243,944 | ||
| Total liabilities and stockholders' equity | 288,311 | 322,101 | ||
Voyager Therapeutics, Inc. (VYGR)
Voyager Therapeutics, Inc. (VYGR)